Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
110Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $22.54M | $-27.28M | $-0.98 |
| 2024 | $37.04M | $12.45M | $0.49 |
| 2023 | $31.46M | $10.55M | $0.41 |
| 2022 | $35.09M | $12.57M | $0.02 |
| 2021 | $27.72M | $11.68M | $1.40 |
Social Signal Score
Valuation
BDMDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsglobenewswire.com·5d ago·Positive
Baird Medical and Alpmed Enter Strategic Partnership to Advance Irreversible Electroporation (IRE) Technology Globally NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (“Baird Medical” or the “Company”) and Tianjin Yuanshan Medical Technology Co., Ltd., operating under the Alpmed brand (“Alpmed”), a China-based innovator in irreversible electroporation (“IRE”) technology, announced the signing of a strategic cooperation agreement to establish a lo
View source ↗